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Results:
n % 10 Year LR free
RT + TAM 98 100 ± 0
RT only 110 93 ± 3
TAM only 107 93 ± 3
Neither 96 82 ± 4
Entry was also allowed to 2-way randomisation for units which
had opted to give RT or TAM to all their cases. Analysis by ran-
domisation then allowed RT versus no RTwith both arms includ-
ing some cases receiving TAM by elective choice of Unit (or) TAM
versus no TAM, both including some cases receiving elective RT.
Results:
n % 10 Year
LR free
% 15 Year
LR free
W-G p
RT 571 97 ± 1 93 ± 1 20.5 <0.000
No RT 568 88 ± 2 86 ± 2
TAM 213 96 ± 2 92 ± 4 12.3 <0.000
No TAM 217 87 ± 3 83 ± 3
Analysis by treatment received confirms that results from ran-
domisation (intention to treat).
Survival overall (all cases) is 91 ± 1% at 10 years.
Conclusion:
1. Omission of any adjuvant therapy led to a recurrence rate of
1.8% per annum. This was reduced by the use of either TAM
only or RT only.
2. Use of both TAM and RT produced no LR’s.
doi:10.1016/j.ejcsup.2010.06.048
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Objectives: To assess whether in older women with ‘low risk’
axillary node negative breast cancer (T0–2, N0, M0) treated by
breast conserving surgery and adjuvant endocrine therapy the
omission of post-operative radiotherapy affects quality of life
and is cost-effective.
Design: Randomised controlled multicentre trial.
Participants: Patients (255) with follow up to 5 years from the
end of recruitment.
Interventions: Whole breast radiotherapy (40–50 Gy) or no
breast radiotherapy.
Main outcome measures: Quality of life, anxiety and depression,
cost effectiveness.
Results: No difference in overall quality of life or anxiety and
depression was found. However, in the subscales of the EORTC
QLQ C30 and BR23 questionnaires, there were significantly higher
levels of insomnia within the non-irradiated group. By contrast,
the irradiated patients reported higher levels of breast symptoms,
and social function was slower to recover. The mean Quality
Adjusted Life Years were similar in the two arms with marginally
higher levels in the radiotherapy arm. The additional cost of pro-
viding radiotherapy was £2128 per patient. Local recurrence rates
at 5 years were 6% (95% CI 0–12%) in the non-irradiated group and
0% in the irradiated group.
Conclusion: Breast radiotherapy is tolerated well by most older
breast cancer patients without impairing their overall health
related quality of life (HRQOL). Concerns about HRQOL should
not be a primary consideration when deciding whether or not
to recommend postoperative radiotherapy after breast conserving
surgery and adjuvant endocrine therapy. The ‘no radiotherapy
option’ is cost effective in the short term.
doi:10.1016/j.ejcsup.2010.06.049
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Background: The Cambridge Breast IMRT Trial demonstrated
that improving dose distribution using IMRT leads to significant
reduction in telangiectasia at comparatively early follow-up.
The secondary aim was to elucidate the influence of patient-
related and surgical factors on late toxicity and cosmesis.
Method: The influence of such factors on late toxicity assessed
using photographic, clinical and patient-reported endpoints at 2
years following radiotherapy was analysed in 1014 patients.
Results: Patients with a moderate or poor baseline surgical cos-
mesis had an increased risk of moderate or poor overall cosmesis
(odds ratio (OR) = 38.19; 95% CI 21.9–66.7; p < 0.0005), and of devel-
oping any clinically assessed breast shrinkage (OR = 4.96; 95% CI
3.67–6.71, p < 0.0005) and induration (OR = 2.78; 95% CI 1.92–4.01,
p < 0.0005) at 2 years. Increased breast volume was significantly
associated with the development of several late toxicity end-
points (p < 0.0005). Current smokers had an increased risk of
developing pigmentation (OR = 2.09, 95% CI 1.23–3.54; p = 0.006).
Post-operative infection requiring antibiotics was associated with
increased risk of telangiectasia (OR = 3.39, 95% CI 1.94–5.91;
p < 0.0005) and breast oversensitivity (OR = 1.78, 95% CI 1.27–
2.49; p = 0.001).
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